Taysha Gene Therapies マネジメント

マネジメント基準チェック /34

Taysha Gene Therapiesの CEO はSean Nolanで、 Dec2022年に任命され、の在任期間は 1.92年です。の年間総報酬は$ 1.52Mで、 39.4%給与と60.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.001%を直接所有しており、その価値は$ 2.89K 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と3.8年です。

主要情報

Sean Nolan

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	39.4%
CEO在任期間	1.9yrs
CEOの所有権	0.0006%
経営陣の平均在職期間	1.9yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

CEO報酬分析

Taysha Gene Therapies の収益と比較して、Sean Nolan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$23m
Jun 30 2024	n/a	n/a	-US$114m
Mar 31 2024	n/a	n/a	-US$118m
Dec 31 2023	US$2m	US$600k	-US$112m
Sep 30 2023	n/a	n/a	-US$214m
Jun 30 2023	n/a	n/a	-US$124m
Mar 31 2023	n/a	n/a	-US$133m
Dec 31 2022	US$2m	US$25k	-US$166m
Sep 30 2022	n/a	n/a	-US$161m
Jun 30 2022	n/a	n/a	-US$186m
Mar 31 2022	n/a	n/a	-US$193m
Dec 31 2021	US$321k	n/a	-US$175m
Sep 30 2021	n/a	n/a	-US$142m
Jun 30 2021	n/a	n/a	-US$106m
Mar 31 2021	n/a	n/a	-US$87m
Dec 31 2020	US$457k	n/a	-US$60m

報酬と市場: Seanの総報酬 ($USD 1.52M ) は、 US市場 ($USD 2.18M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sean Nolan (56 yo)

1.9yrs

在職期間

US$1,522,515

報酬

Mr. Sean P. Nolan serves as Executive Chairman of Jaguar Gene Therapy, LLC. Mr. Nolan has been Chairman of the board at Taysha Gene Therapies, Inc since March 2020 and serves as its Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sean Nolan	CEO & Chairman	1.9yrs	US$1.52m	0.00057% $ 2.9k
Sukumar Nagendran	President	1.9yrs	US$1.25m	0.017% $ 84.5k
Kamran Alam	CFO & Corporate Secretary	4.3yrs	US$975.40k	0.077% $ 391.0k
Hayleigh Collins	Director of Corporate Communications & Investor Relations	no data	データなし	データなし
Tracy Porter	Chief People Officer	3.8yrs	データなし	データなし
Frederick Porter	Chief of Staff & Technical Operations Officer	1.8yrs	データなし	データなし
Emily McGinnis	Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead	no data	データなし	データなし
Sean McAuliffe	Chief Business Officer	no data	データなし	データなし
Steven Gray	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	no data	データなし	データなし
Berge Minassian	Chief Medical Advisor of UT Southwestern Gene Therapy Program	no data	データなし	データなし
Rumana Haque-Ahmed	Chief Regulatory Officer	no data	データなし	データなし
Meredith Schultz	Chief Medical Officer	less than a year	データなし	データなし

1.9yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: TSHAの経営陣は経験豊富とはみなされません ( 1.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Sean Nolan	CEO & Chairman	4.7yrs	US$1.52m	0.00057% $ 2.9k
Sukumar Nagendran	President	4.3yrs	US$1.25m	0.017% $ 84.5k
Phillip Donenberg	Independent Director	4.3yrs	US$73.82k	0.056% $ 281.9k
Sean Stalfort	Independent Director	1.4yrs	US$35.09k	0.94% $ 4.8m
Paul Manning	Board Observer	1.4yrs	US$22.81k	12.12% $ 61.3m
Wendy Chung	Independent Scientific Advisory Board	3.8yrs	データなし	データなし
Deborah Bilder	Independent Scientific Advisory Board	3.8yrs	データなし	データなし
David Dimmock	Independent Scientific Advisory Board	3.8yrs	データなし	データなし
Laura Sepp-Lorenzino	Independent Director	4yrs	US$76.90k	0% $ 0
Alison Long	Independent Director	less than a year	US$77.96k	0% $ 0
Gerald Lipshutz	Independent Scientific Advisory Board	3.8yrs	データなし	データなし
Benedikt Schoser	Member of Independent Scientific Advisory Board	3.1yrs	データなし	データなし

3.8yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: TSHAの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Taysha Gene Therapies マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Board Observer recently bought US$163k worth of stock

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

CFO & Corporate Secretary notifies of intention to sell stock

Insider recently sold US$61k worth of stock

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Taysha Gene Therapies, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

マネジメント基準チェック /34